The Effects of Glucagon-like Peptide-1 on Human Megakaryocytes and Platelets
Cardiovascular disease is the most common cause of morbidity and mortality in type 2 diabetes. Short-term studies of glucagon-like peptide-1 (GLP-1)-targeted therapies suggest potential beneficial effects on cardiovascular outcomes. The mechanism behind this unexpectedly rapid effect is not known. I...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/42699 |